JP2002504505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002504505A5 JP2002504505A5 JP2000533099A JP2000533099A JP2002504505A5 JP 2002504505 A5 JP2002504505 A5 JP 2002504505A5 JP 2000533099 A JP2000533099 A JP 2000533099A JP 2000533099 A JP2000533099 A JP 2000533099A JP 2002504505 A5 JP2002504505 A5 JP 2002504505A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- butorphanol
- composition according
- oil
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 26
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 7
- -1 fatty acid ester Chemical class 0.000 description 6
- 229960001113 butorphanol Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical group CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical group OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3021798A | 1998-02-25 | 1998-02-25 | |
| US09/030,217 | 1998-02-25 | ||
| PCT/US1999/004113 WO1999043300A1 (en) | 1998-02-25 | 1999-02-25 | Butorphanol sustained release formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002504505A JP2002504505A (ja) | 2002-02-12 |
| JP2002504505A5 true JP2002504505A5 (enExample) | 2006-04-20 |
Family
ID=21853121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000533099A Pending JP2002504505A (ja) | 1998-02-25 | 1999-02-25 | ブトルファノール持続放出性製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6197344B1 (enExample) |
| EP (1) | EP1056443B1 (enExample) |
| JP (1) | JP2002504505A (enExample) |
| AT (1) | ATE265846T1 (enExample) |
| AU (1) | AU753278B2 (enExample) |
| CA (1) | CA2321924A1 (enExample) |
| DE (1) | DE69917000T2 (enExample) |
| WO (1) | WO1999043300A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6680067B2 (en) * | 2001-11-26 | 2004-01-20 | Oliver Yoa-Pu Hu | Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same |
| PL223471B1 (pl) * | 2002-03-15 | 2016-10-31 | Cypress Bioscience Inc | Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego |
| AU2003272601B2 (en) * | 2002-09-20 | 2009-05-07 | Alpharma Pharmaceuticals, Llc | Sustained-release opioid formulations and methods of use |
| US20060003004A1 (en) * | 2002-10-25 | 2006-01-05 | Collegium Pharmaceutical, Inc. | Pulsatile release compositions of milnacipran |
| US20040132826A1 (en) * | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| US20040228830A1 (en) * | 2003-01-28 | 2004-11-18 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
| RU2254852C1 (ru) * | 2004-01-23 | 2005-06-27 | Ефим Давыдович Нежинский | Раствор для инъекций, обладающий выраженным анальгетическим действием, и способ его получения |
| WO2008106571A2 (en) * | 2007-02-28 | 2008-09-04 | Abbott Laboratories | Sustained release parenteral formulations of buprenorphine |
| CA2816420C (en) * | 2010-10-29 | 2018-01-16 | Najib Babul | Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
| US11234974B2 (en) | 2015-05-28 | 2022-02-01 | Lumosa Therapeutics Co., Ltd. | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester |
| CN106376232B (zh) | 2015-05-28 | 2021-06-11 | 顺天医药生技股份有限公司 | 用于持续释放癸二酰二纳布啡酯的药物制剂 |
| US10183018B2 (en) | 2015-05-28 | 2019-01-22 | Lumosa Therapeutics Co., Ltd. | Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester |
| CN111904928A (zh) * | 2019-05-07 | 2020-11-10 | 江苏恒瑞医药股份有限公司 | 一种包含布托啡诺的可注射的药物组合物及其制备方法 |
| CN116818928B (zh) * | 2023-04-28 | 2024-04-19 | 杭州沐源生物医药科技有限公司 | 一种酒石酸布托啡诺注射液中杂质的分离检测方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE788478A (fr) | 1971-09-08 | 1973-03-06 | Bristol Myers Co | Procede de preparation de composes analgesiques |
| CA1098444A (en) * | 1975-05-26 | 1981-03-31 | Leo Geller | Peptide preparations with prolonged action |
| US4338324A (en) * | 1981-03-17 | 1982-07-06 | Mcneilab, Inc. | Analgesic potentiation |
| US4322427A (en) | 1981-04-16 | 1982-03-30 | Bristol-Myers Company | Analgetic compositions and methods of use |
| US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| AU614527B2 (en) * | 1987-07-24 | 1991-09-05 | Nexstar Pharmaceuticals, Inc. | Opioid analgesic liposomal delivery-release system |
| FR2663223B1 (fr) * | 1990-06-14 | 1994-12-02 | Af Aplicaciones Far Lab | Forme galenique parenterale. |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
| GB9226905D0 (en) * | 1992-12-24 | 1993-02-17 | Wellcome Found | Pharmaceutical preparation |
| JP2596255Y2 (ja) | 1993-03-23 | 1999-06-07 | ナカミチ株式会社 | ディスク再生装置 |
| DE69603577T2 (de) | 1995-02-10 | 1999-11-25 | Medtronic, Inc. | Verfahren und vorrichtung zur verabreichung von analgetika |
| TW487572B (en) * | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
-
1999
- 1999-02-25 WO PCT/US1999/004113 patent/WO1999043300A1/en not_active Ceased
- 1999-02-25 AT AT99936027T patent/ATE265846T1/de not_active IP Right Cessation
- 1999-02-25 CA CA002321924A patent/CA2321924A1/en not_active Abandoned
- 1999-02-25 DE DE69917000T patent/DE69917000T2/de not_active Expired - Fee Related
- 1999-02-25 AU AU33112/99A patent/AU753278B2/en not_active Ceased
- 1999-02-25 JP JP2000533099A patent/JP2002504505A/ja active Pending
- 1999-02-25 EP EP99936027A patent/EP1056443B1/en not_active Expired - Lifetime
- 1999-10-28 US US09/429,391 patent/US6197344B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002504505A5 (enExample) | ||
| US11173209B2 (en) | Compositions for drug administration | |
| JP4892148B2 (ja) | 活性物質ジアモルフィンからなる医薬生成物およびオピエート嗜癖の処置方法におけるその使用 | |
| ES2569949T3 (es) | Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina | |
| JP2007507538A5 (enExample) | ||
| CA2601289A1 (en) | Once-a-day oxycodone formulations | |
| JP2005515966A (ja) | 鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与 | |
| RU97103563A (ru) | Композиции длительного высвобождения венлафаксин гидрохлорида, композиция пленочного покрытия, способ обеспечения терапевтически активной концентрации венлафаксина и способ исключения нулевых и пиковых концентраций лекарственного средства | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| NO20022014L (no) | En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon | |
| WO2006039692A3 (en) | Modified release ibuprofen dosage form | |
| NZ519993A (en) | Compositions for delivery of a cortisol antagonist | |
| JP2002519425A5 (enExample) | ||
| US4831057A (en) | Antisnoring agent | |
| JP2003534246A5 (enExample) | ||
| WO2003004024A1 (en) | Injectable sustained-release microspheres of huperzine a compounds | |
| JP5116665B2 (ja) | 口腔投与のためのアポモルフィンの薬学的配合物 | |
| KR101307650B1 (ko) | 구역에 대한 경피 방법 및 패치 | |
| JP2000273061A (ja) | テルペノイドエマルション | |
| JP2002537232A5 (enExample) | ||
| SK134395A3 (en) | Transdermal therapeutical agent and preparation method thereof | |
| HU227338B1 (en) | Pharmaceutical compositions of alkylsulphonamides 5ht1 agonists for rectal administration | |
| US20180000942A1 (en) | Compositions for drug administration | |
| JP2002523458A5 (enExample) | ||
| JP2002522462A5 (enExample) |